Invasive Candidiasis in Critical Care
ConditionInvasive Candidiasis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age12+
SponsorUniversity Hospital Ostrava
About this trial
The combination of acute phase marker monitoring and the "T2Candida" assay (name of the test) will represent an acceleration of the identification of the causative agent of mycotic infection, a significant improvement in the specificity and positive predictive value of this strategy in the diagnosis of invasive candidiasis and candidemia in ICU patients, thereby improving the clinical condition of patients and reducing the cost of specific antifungal therapy.
Eligibility criteria
Qualifiers
critically ill patients
new onset sepsis
rise in body temperature >38°C according to The Third Consensus Definitions for Sepsis and Septic Shock
colonization with Candida spp. from more than 1 non-sterile site
Disqualifiers
not signing the informed consent with participation in the study
administration of antifungal therapy prior to collection of the biological material required for the study
Trial design
Treatments tested in this trial
- Invasive candidiasis test
- Urine sample collection for future research
Treatment groups
100 Participants
are divided into 1 treatment groupSponsors and collaborators
University Hospital Ostrava
Lead sponsor
University Hospital, Motol
Collaborator
Source ClinicalTrials.gov